Aptahem AB (publ) announces today that the company has received information that the European Patent Office (EPO) has issued an Intention to Grant of the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant...
Read MoreBioStock published an article on 1 July 2021 about Aptahem, which can be read in full below. Since 2019, Aptahem has collaborated with the Cardiovascular Research Centre (CVRC) at Örebro University to better understand certain mechanisms behind Apta-1’s effect....
Read MoreAptahem AB (publ) announces today that the company has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance fo the US patent application 16/652,926 entitled A nucleic acid molecule with anti-inflammatory...
Read MoreAptahem AB (publ) announce today that the collaboration with the Cardiovascular Research Centre (CVRC) at Örebro University to map the details behind Apta-1’s effects with the support from the Knowledge Foundation’s Prospect Call now has generated results that clarify...
Read MoreBioStock published an article on 26 May 2021 about Aptahem, which can be read in full below. The most anticipated milestone for sepsis company Aptahem is initiating first-in-human trials with candidate Apta-1, which is planned for next year. BioStock...
Read More